Palatin Technologies fights the perils of poor health with protein and peptide-based therapies. The company researches and develops drugs that target melanocortin (MC) receptors and natriuretic receptors in the brain. MC-targeted drugs could be used in the treatment of obesity, diabetes, and sexual dysfunction. While natriuretic (a type of peptide) focused treatments are being studied for the treatment of heart failure, asthma, and other cardiovascular diseases. Many of the company's research programs use its MIDAS (Metal Ion-induced Distinctive Array of Structures) technology to design drugs that mimic peptides. The company's lead candidate is bremelanotide to treat sexual dysfunction in men and women.